Mandate

Vinge has advised CELLINK in a directed issue of new shares

Vinge has advised CELLINK AB (publ) in connection with a directed issue of new shares which will generate approximately MSEK 377 for CELLINK.

The subscription price was determined through an accelerated book‑building and corresponds to a discount of 3.4 per cent compared with the volume‑weighted average listed price during January on Nasdaq First North Growth Market. In addition to considerable support from existing shareholders, several new Swedish and institutional shareholders subscribed for the new issue of shares. An amount of MSEK 150 from the proceeds in relation to the new issue of shares will be used to finance the company’s organic growth plan, future operating capital requirements, etc. and the remaining proceeds can be used to finance strategic acquisitions.

Vinge’s team consisted of Anders StridEdin Agic and Anna Ståhlklo.

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025